Genfit (GNFT)

3.03
-0.07(-2.26%)
  • Volume:
    118,669
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    3.03 - 3.12
  • Type:Equity
  • Market:France
  • ISIN:FR0004163111

GNFT Overview

Prev. Close
3.1
Day's Range
3.03-3.12
Revenue
5.32M
Open
3.1
52 wk Range
3.05-6.24
EPS
-1.03
Volume
118,669
Market Cap
141.8M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
85,420
P/E Ratio
-
Beta
1.12
1-Year Change
-4.56%
Shares Outstanding
45,741,321
Next Earnings Date
Nov 08, 2021
What is your sentiment on Genfit?
or
Vote to see community's results!

Genfit News

Genfit Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Genfit Company Profile

Genfit Company Profile

Employees
122
Market
France

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

Read More
  • what's the reason of fall of Genfit?
    0
    • i also want to know
      0
    • dont worry it Will raise soon 😉
      0
  • it cheap to buy
    0
    • Trials for NASH will continue after dataset correction
      1
      • they failed the drug test and NASH drug was the only viable drug that they were developing , so practically they lost almost all value with that failure...
        1
        • not all value but a drug development. they have so many programs to continue
          0
      • damn what was wrong w this beast? from 2x all the way down to 5 w low volume?
        0
        • Whats the status , will it still go down ?
          0
          • Yes
            0
        • this baby Is the brother of contravirpharma (HEPA) .. same diseases.
          0
          • what do you mean?
            0
        • WHAT IS THE BEST STOCK TO BUY TODAY ??/ ANT RECOMMENDATION
          0
          • does anyone have an explaination for the sudden fall same day of the Nasdaq trading?
            0
            • Mathieu Gandrille ah you mean to buy because it would be oversold
              0
            • MfB Iod  i mean if 5 i would buy, and sell at 8
              0
            • Mathieu Gandrille are you a KOL?
              0
          • DATA is opn in 1Q 2019?
            0
            • Huge potential (x3-4 by Q1 2019) After results n PBC mid December. just by comparing with competitors market cap with similar pipeline (intercept, Gilead)
              0
              • DATA is opn in 1Q 2019?
                0
            • Huge potential (x3-4 by Q1 2019) After results n PBC mid December. just by comparing with competitors market cap with similar pipeline (intercept, Gilead)
              0
              • yep this is a sleeping giant
                0
            • cannot understand how everyone is sleeping on this, unbelievable
              0
              • MfB Iod i know, but it seems they want to hold all the markets for them, so always delaying the deadlines, the news and the progress.. They don't want to associate with other pharma to have the final product earlier.. and one big thing is that many hedge fund shorted it thats why it goes down, now only private like you and me have it.. . . But yes it has a HUGE potential.
                0
              • Giuliano Rossi what do you mean hold all the markets for them? I don't think they are delaying. Their diagnostic product is the only one around and will be used with all the other NASH drugs in combination. I'm interested more in their diagnostic rather than the actual Elafibranor. Long GENFIT
                0
              • MfB Iod instead or dealing with other pharma a have a final product done, they want to do all by themself. by doing this they are late and late in every step. Mr. Mouney admit it.. Second this we've seen on continuous shares holding decrease cause people can't hold it anymore while it was always and always going down. from 33 to 17, off course at some point they exited.. Hopefully they will not postpone the result of phase 3 test...
                0
            • Nice topic here about genfit ahah :)
              0
              • The main competitor to Intercept is GENFIT, a pure golden nugget with a pluripotent molecule (GFT505) curing NASH and cardio vascular problems ( not like others, follow my eyes ..). . at the END of the 2b Phase,. . with an excellent safety independant report ,. . with a fast track agreement form the FDA .. FOR NASH ( follow again my eyes ). . and for an valuation 1/10 of is first competitor (follow my ..) ... . you can add that the Genfit molecule will be likely the first on the market for the NASH because of his safety report already published.. . the only problem ... it is an european molecule not easy to trade as US ones. . but on NASDAQ only next year .. better to get some before, the share is close to 34 $ ( with a close amount of shares). . code on the grey market GNFTF. . trading code GNFT.PA
                0
                • repart demain haussier
                  0
                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.